AARTIPHARM
Aarti Pharmalabs Limited
NSELast Traded Price
₹881.95
3.6 (0.41%)
Open
₹878.35
High
₹883.15
Low
₹845.15
Prev Close
₹878.35
Industry
Pharmaceuticals
Market Cap
7997.51 Cr
Filing History
Recent corporate announcements and filings for AARTIPHARM
Routine
Negative
2026-09-30 17:46
CRITICAL RED FLAG DETECTED
- Aarti Pharmalabs Limited has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad.
- The petition challenges the order dated August 29, 2026, passed by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
- The challenged order levied a stamp duty and penalties totaling ₹59.50 Crore regarding the Scheme of Arrangement (Demerger) sanctioned by the Hon'ble NCLT.
Governance
Neutral
2026-09-30 11:06
- Aarti Pharmalabs Limited announced the reconstitution of its Nomination and Remuneration Committee.
- The reconstitution was approved by the Board of Directors on September 30, 2026, and is effective from October 01, 2026.
- New committee includes Smt. Jeenal Savla as Chairperson, along with Dr. Vinay Nayak, Shri Pradeep Thakur, and Shri Rashesh Gogri as members.
Routine
Neutral
2026-09-28 10:59
- Trading window closed from October 01, 2026.
- Closure remains until 48 hours after declaration of Q2 FY27 financial results.
- Date of the Board Meeting will be announced in due course.
Governance
Neutral
2026-09-23 18:56
- Rajendra Gogri ceased as Non-Executive Non-Independent Director (effective Sep 22, 2026).
- Hetal Gogri Gala re-designated from Managing Director to Whole-time Director (effective Oct 1, 2026).
- Rashesh C. Gogri appointed as Managing Director (from Non-Executive Director) (effective Oct 1, 2026).
Business Update
Positive
2026-09-22 18:18
- Investor Presentation at 7th AGM on Sep 22, 2026.
- Targets 15-18% Revenue & EBITDA CAGR over 3-4 years.
- FY26 consolidated financials not comparable YoY due to JV accounting changes.
- ~₹400 Cr capex for FY26; similar FY27 outlook, with Greenfield and Brownfield expansions.
Governance
Negative
2026-09-02 20:44
CRITICAL RED FLAG DETECTED
- Aarti Pharmalabs received an order levying ₹59.50 Crores (stamp duty and penalty) related to its 2022 demerger. The company plans to challenge the order.
Governance
Negative
2026-08-31 19:49
CRITICAL RED FLAG DETECTED
- Shri G.M. Naidu, Senior Management Personnel (Manufacturing/ Sr. General Manager / Chief of Operations), has resigned due to personal commitments and professional aspirations. His resignation was tendered on June 10, 2026, and he will be relieved from services on August 31, 2026.
Business Update
Neutral
2026-08-29 19:06
- Submitted the Business Responsibility and Sustainability Report for the Financial Year 2025-26.
- Filed as per Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The report details the company's ESG performance, policies, and management processes, with the full report available on its website.
Financials
Positive
2026-08-17 17:28
- Final Dividend for FY 2025-26 of ₹2.00/- per equity share (40%).
- Record Date for final dividend payment is Tuesday, September 15, 2026.
- The dividend will be paid on or before Tuesday, October 20, 2026, subject to approval at the AGM on September 22, 2026.
Routine
Neutral
2026-08-17 16:32
New Filing detected. See link for details.
Business Update
Neutral
2026-08-10 21:43
- Aarti Pharmalabs Limited has uploaded the audio recording of its Investors/Analyst Earnings Conference Call.
- The call was regarding the unaudited financial results for the first quarter ended June 30, 2026.
- The recording is accessible via the link: https://www.aartipharmalabs.com/q1-fy-27.
Business Update
Neutral
2026-08-10 13:19
- Aarti Pharmalabs Limited submitted an Investor Presentation related to its Q1 FY27 results.
- The presentation provides a company overview, highlighting its manufacturing capabilities, R&D, and key milestones.
- Geographical sales for Q1 FY27 were reported as 40% Domestic and 60% International.
- The presentation includes historical standalone revenue and EBITDA margins up to Q1 FY26, but detailed comparative financial results for Q1 FY27 (Revenue, EBITDA, PAT) are not provided in this document.
Routine
Neutral
2026-08-07 21:07
New Filing detected. See link for details.
Routine
Neutral
2026-08-07 20:32
New Filing detected. See link for details.
Routine
Neutral
2026-08-07 20:11
New Filing detected. See link for details.
Routine
Neutral
2026-08-07 20:03
New Filing detected. See link for details.